LOS ANGELES, Jan. 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period" ...

AstraZeneca (AZN) stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations at its China subsidiary. However, the overall drug and biotech sector has also done poorly in the past three months after Trump announced the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services, the agency that oversees the FDA.This, coupled with disappointing third-quarter sales and profits, guidance cuts and pipeline setbacks took a t ...

Pharmaceutical Industry Overview - Novo Nordisk and AstraZeneca are among the largest companies in the pharmaceutical industry, both delivering strong financial results in 2024 despite stock price declines [1] - AstraZeneca's shares are down 2% over the trailing-12-month period, while Novo Nordisk's shares are down 14% [1] Novo Nordisk Analysis - Novo Nordisk has a 33.9% share of the diabetes care market as of August 2024, up from 33.3% a year prior [3] - The company holds a 55.6% share of the GLP-1 drug space, compared to 54.4% in August 2023 [3] - Novo Nordisk's GLP-1 drugs Wegovy and Ozempic have driven rapid financial growth [3] - The weight loss market is projected to grow rapidly, with Novo Nordisk having an attractive pipeline in this field [4] - CagriSema, a weight loss drug candidate, showed 22.7% average weight loss in a 68-week study, outperforming Wegovy and Eli Lilly's Zepbound [5] - Novo Nordisk has promising candidates in rare diseases and neurological conditions like Alzheimer's and Parkinson's [6] AstraZeneca Analysis - AstraZeneca has a diversified pipeline spanning oncology, rare diseases, cardiovascular, renal, metabolism, respiratory, immunology, and vaccine therapies [8] - The company has 199 programs in its pipeline, including several promising candidates in the weight loss area [10] - AstraZeneca faces challenges in China due to an insurance fraud investigation and the arrest of its China president, Leon Wang [10][11] - Despite higher quarterly revenue, AstraZeneca's earnings per share are lower [12] Comparative Analysis - Novo Nordisk's revenue growth is expected to outpace AstraZeneca's in the short to mid-term due to its strong GLP-1 medicines and AstraZeneca's potential sales decline in China [14] - Novo Nordisk's recent issues are less damaging to its prospects compared to AstraZeneca's challenges [14]

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit- ...

Lawsuit Details - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of AstraZeneca PLC securities between February 23, 2022, and December 17, 2024 [1] - The lawsuit alleges that AstraZeneca made materially false and/or misleading statements and/or failed to disclose key information during the Class Period [3] - The allegations include AstraZeneca engaging in insurance fraud in China, leading to heightened legal exposure and the detention of the AstraZeneca China President by Chinese authorities [3] - The lawsuit claims that AstraZeneca understated its legal risks and that the revelations could materially harm its business activities in China [3] - Investors allegedly suffered damages when the true details entered the market [3] Legal Process - A class action lawsuit has already been filed, and potential lead plaintiffs must move the Court no later than February 21, 2025 [1][2] - No class has been certified yet, and investors are not represented by counsel unless they retain one [4] - Investors may select their own counsel or remain absent class members without taking action [4] - The ability to share in any potential future recovery is not dependent upon serving as lead plaintiff [4] Compensation and Fees - Investors who purchased AstraZeneca securities during the Class Period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement [7] Rosen Law Firm Background - Rosen Law Firm specializes in securities class actions and shareholder derivative litigation, representing investors globally [8] - The firm achieved the largest ever securities class action settlement against a Chinese company at the time [8] - Ranked No 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and consistently ranked in the top 4 since 2013 [8] - Recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [8] - Founding partner Laurence Rosen was named a Titan of Plaintiffs' Bar by Law360 in 2020 [8] Contact Information - Investors can join the AstraZeneca class action by visiting the Rosen Law Firm website or contacting Phillip Kim, Esq toll-free at 866-767-3653 or via email [2][9][12] - Updates on the case can be followed on LinkedIn, Twitter, and Facebook [10]

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=118944&from=4 CLASS PERIOD: February 23, 2022 t ...

NEW ORLEANS, Dec. 27, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 21, 2025 to file lead plaintiff applications in a securities class action lawsuit against AstraZeneca PLC (the "Company") (NasdaqGS: AZN), if they purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"). This action is pending in the United States Distric ...

Investigation Overview - Pomerantz LLP is investigating claims on behalf of AstraZeneca investors regarding potential securities fraud or unlawful business practices [2][3] - The investigation involves AstraZeneca and certain officers and/or directors [3] Market Impact - AstraZeneca's ADR price fell $5 16 per ADR or 7 22% to close at $66 27 per ADR on November 5 2024 [5] Expanded Investigation - The fraud investigation into AstraZeneca has expanded to include several Chinese government agencies implicating dozens of senior executives at the company [6] Firm Background - Pomerantz LLP is a premier firm in corporate securities and antitrust class litigation with offices in multiple global cities [4] - The firm has a history of recovering multimillion-dollar damages awards for class members [4]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

AstraZeneca (AZN) and its Japanese partner Daiichi Sankyo announced that they have voluntarily withdrawn the marketing authorization application (MAA) for their antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd).The MAA sought approval of Dato-DXd for treating adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase III study.The companies decided to withdraw the MAA for Dato-DXd in nonsquamous NSCLC following feedback ...